LIMITED-FIELD RADIOTHERAPY AS SALVAGE TREATMENT OF LOCALIZED PERSISTENT OR RECURRENT EPITHELIAL OVARIAN-CANCER

被引:15
作者
DAVIDSON, SA
RUBIN, SC
MYCHALCZAK, B
SAIGO, PE
LEWIS, JL
CHAPMAN, D
HOSKINS, WJ
机构
[1] MEM SLOAN KETTERING CANC CTR, DEPT SURG, GYNECOL SERV, NEW YORK, NY 10021 USA
[2] MEM SLOAN KETTERING CANC CTR, DEPT RADIAT ONCOL, NEW YORK, NY 10021 USA
[3] MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, NEW YORK, NY 10021 USA
[4] MEM SLOAN KETTERING CANC CTR, DEPT EPIDEMIOL & BIOSTAT, BIOSTAT SERV, NEW YORK, NY 10021 USA
关键词
D O I
10.1006/gyno.1993.1302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thirty-five patients with persistent or recurrent epithelial ovarian cancer were treated with salvage pelvic or para-aortic radiotherapy for disease limited to the pelvis (29), para-aortic retroperitoneum (5), or vaginal cuff (1). Prior therapy included a median of 3 chemotherapeutic drugs (range, 1-7) over a median of 12 cycles (range, 5-39); 12 patients had received intraperitoneal chemotherapy. The median number of prior laparotomies was 3 (range, 2-5). Including pelvic boosts, the median dose delivered to the treatment field was 4600 cGy (range, 4000-7000); 2 patients received additional treatment with a permanent 125I implant. All patients completed therapy, although 5 (14%) with grade 3 toxicity required a treatment break. Late bowel complications unrelated to recurrence occurred in 3 patients (9%). Median actuarial and progression-free survivals for all patients from start of radiotherapy were 40 and 14 months, respectively. At least 16 of 26 (62%) recurrences involved the treatment field. Multiple prognostic factors were evaluated in terms of recurrence, survival, and acute and chronic complications, but no significant prognosticators were detected. These findings indicate that limited-field salvage radiotherapy has an acceptable complication rate and may prolong the symptom-free survival interval in selected patients. © 1993 by Academic Press, Inc.
引用
收藏
页码:349 / 354
页数:6
相关论文
共 20 条
[1]   THE IMPACT OF WHOLE-ABDOMEN RADIOTHERAPY ON SURVIVAL IN ADVANCED OVARIAN-CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER CHEMOTHERAPY [J].
BOLIS, G ;
ZANABONI, F ;
VANOLI, P ;
RUSSO, A ;
FRANCHI, M ;
SCARFONE, G ;
PECORELLI, S .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :150-154
[2]   CHEMOTHERAPY VERSUS RADIOTHERAPY IN THE MANAGEMENT OF OVARIAN-CANCER PATIENTS WITH PATHOLOGICAL COMPLETE RESPONSE OR MINIMAL RESIDUAL DISEASE AT 2ND LOOK [J].
BRUZZONE, M ;
REPETTO, L ;
CHIARA, S ;
CAMPORA, E ;
CONTE, PF ;
ORSATTI, M ;
VITALE, V ;
RUBAGOTTI, A ;
ROSSO, R .
GYNECOLOGIC ONCOLOGY, 1990, 38 (03) :392-395
[3]  
DEMBO AJ, 1985, CANCER, V55, P2285, DOI 10.1002/1097-0142(19850501)55:9+<2285::AID-CNCR2820551436>3.0.CO
[4]  
2-4
[5]  
DISAIA PJ, 1993, CLIN GYNECOLOGIC ONC, P710
[6]   CHEMOTHERAPEUTIC AND SURGICAL INDUCTION OF PATHOLOGICAL COMPLETE REMISSION AND WHOLE ABDOMINAL IRRADIATION FOR CONSOLIDATION DOES NOT ENHANCE THE CURE OF STAGE-III OVARIAN-CARCINOMA [J].
FUKS, Z ;
RIZEL, S ;
BIRAN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :509-516
[7]  
HACKER NF, 1985, OBSTET GYNECOL, V65, P60
[8]   WHOLE ABDOMINAL AND PELVIC IRRADIATION IN PATIENTS WITH MINIMAL DISEASE AT 2ND-LOOK SURGICAL REASSESSMENT FOR OVARIAN-CARCINOMA [J].
HOSKINS, WJ ;
LICHTER, AS ;
WHITTINGTON, R ;
ARTMAN, LE ;
BIBRO, MC ;
PARK, RC .
GYNECOLOGIC ONCOLOGY, 1985, 20 (03) :271-280
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]  
LOUIE KG, 1985, CANCER RES, V45, P2110